The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study
- 28-11-2021
Gepubliceerd in:
- Auteurs
- Panagiotis Athanassiou
- Anastasios Kotrotsios
- Ioannis Kallitsakis
- Andreas Bounas
- Theodoros Dimitroulas
- Alexandros Garyfallos
- Maria G. Tektonidou
- Giorgos Vosvotekas
- Achilleas Livieratos
- Evangelia Petrikkou
- Gkikas Katsifis
- Gepubliceerd in
- Quality of Life Research | Uitgave 5/2022
Abstract
Purpose
To examine the impact of golimumab, on work productivity, activity limitation, and quality of life (QoL) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).
Methods
This real-world, multicenter, prospective study consecutively enrolled adult consented work-active patients with axSpA or PsA, newly initiated on golimumab as per the approved label. Prior receipt of > 1 prior biologic, or switching from another tumor-necrosis factor inhibitor due to primary non-response or safety reasons was not allowed. The Work Productivity and Activity Impairment-Specific Health Problem and the EuroQol 5-Dimensions (EQ-5D)-5-Level instruments were completed by the patients to assess the impact of golimumab on work productivity and activity impairment, and generic QoL, respectively.
Results
Overall, 121 eligible patients (mean age: 45.4 years; median disease duration: 11.3 months), 51 diagnosed with PsA and 70 with axSpA, were enrolled by 19 rheumatologists. Over a 11.9-month median observation period, < 1% of injections were missed (as collected by patient diaries), and the 12-month golimumab retention rate was 91.7%. At 3, 6, and 12 months post baseline, in the overall population, work productivity loss improved by a median of 31.4%, 44.2%, and 50.0%; activity impairment improved by 40.0%, 40.0%, and 50.0%; and the EQ-5D UK-weighted utility index improved by 0.24, 0.32, and 0.36 points, respectively (p < 0.001 for all). Statistically significant improvements in these measures were also noted in the PsA and axSpA subpopulations.
Conclusion
In the routine care in Greece, golimumab displays beneficial effects on work productivity, daily activities, and QoL in work-active patients with axSpA and PsA.
Trial registration
Trial registration number and date of registration: As per the local regulations the study has been registered at the national registry for non-interventional studies https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=MK8259-6083.
- Titel
- The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study
- Auteurs
-
Panagiotis Athanassiou
Anastasios Kotrotsios
Ioannis Kallitsakis
Andreas Bounas
Theodoros Dimitroulas
Alexandros Garyfallos
Maria G. Tektonidou
Giorgos Vosvotekas
Achilleas Livieratos
Evangelia Petrikkou
Gkikas Katsifis
- Publicatiedatum
- 28-11-2021
- Uitgeverij
- Springer International Publishing
- Gepubliceerd in
-
Quality of Life Research / Uitgave 5/2022
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649 - DOI
- https://doi.org/10.1007/s11136-021-03044-4
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.